Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Goodwill & Intangibles (2022 - 2025)

Catalyst Pharmaceuticals' Goodwill & Intangibles history spans 4 years, with the latest figure at $131.7 million for Q4 2025.

  • For Q4 2025, Goodwill & Intangibles fell 15.96% year-over-year to $131.7 million; the TTM value through Dec 2025 reached $131.7 million, down 15.96%, while the annual FY2025 figure was $131.7 million, 15.96% down from the prior year.
  • Goodwill & Intangibles reached $131.7 million in Q4 2025 per CPRX's latest filing, down from $227.7 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $227.7 million in Q4 2023 to a low of $32.5 million in Q4 2022.
  • Average Goodwill & Intangibles over 4 years is $163.5 million, with a median of $171.4 million recorded in 2023.
  • Peak YoY movement for Goodwill & Intangibles: surged 601.28% in 2023, then plummeted 31.2% in 2024.
  • A 4-year view of Goodwill & Intangibles shows it stood at $32.5 million in 2022, then soared by 601.28% to $227.7 million in 2023, then plummeted by 31.2% to $156.7 million in 2024, then fell by 15.96% to $131.7 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Goodwill & Intangibles are $131.7 million (Q4 2025), $227.7 million (Q3 2025), and $227.7 million (Q2 2025).